Astellas Discontinues Development Of Factor Xa Inhibitor Darexaban; Will Not Pursue Anticoagulants
This article was originally published in PharmAsia News
Executive Summary
TOKYO - There is one less oral Factor Xa inhibitor vying for approval after Astellas Pharma Inc. announced it discontinued global development of darexaban for all indications. Unable to find a partner to co-develop the compound, Astellas is bowing out of the anticoagulant space
You may also be interested in...
Daiichi Sankyo's Edoxaban Enters Its First Market; Eisai "Very Pleased" With Eribulin Japanese Price Listing
TOKYO - Drugmakers introduced a number of new products in Japan this week, including the first launch globally of Daiichi Sankyo Co. Ltd.'s oral factor Xa inhibitor edoxaban, following the release of National Health Insurance price listings
Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets
TOKYO - Unlike its top rival Takeda Pharmaceuticals Co. Ltd., Astellas Pharma Inc. says it will primarily look for organic growth in emerging markets, although the Japanese major is not adverse to M&A if it finds the right opportunity
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).